LGALS1 and neoplasm: Remarkably, blockade of Gal1 with monoclonal antibodies increase CD4+ CD8+ tumor infiltrating lymphocytes in melanoma [112] and lung cancer through T-cell proliferation and the induction of tumor-specific T1-type immunologic response in lymph nodes [35].